Mohsen Kheradpezhouh, MD
Internal Medicine · Melbourne, FLNPI 1346363405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 40.7% of the total. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 7 payments — averaging $35.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$100
- Radius Health, Inc.$55
- Amgen$41
- CSL Behring$28
- Lilly USA, LLC$22
What the payments were for
- Food & beverage$246100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $100 |
| Radius Health, Inc. | 2 | $55 |
| Amgen | 2 | $41 |
| CSL Behring | 1 | $28 |
| Lilly USA, LLC | 1 | $22 |
How this compares
$246 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $18,244 |
| Budesonide | 12 | $2,641 |
| Midodrine Hcl | 16 | $1,839 |
| Sucralfate | 16 | $1,614 |
| Atorvastatin Calcium | 100 | $1,390 |
| Famotidine | 110 | $1,066 |
| Levetiracetam | 51 | $1,062 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 17 | $1,025 |
| Enoxaparin Sodium | 11 | $905 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $748 |
| CeftriaxoneCeftriaxone Sodium | 14 | $646 |
| Hydralazine Hcl | 19 | $626 |
| Amlodipine Besylate | 71 | $562 |
| ClopidogrelClopidogrel Bisulfate | 35 | $447 |
| Metoprolol Tartrate | 42 | $445 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Melbourne
- Ronald CathcartMelbourne$150K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.